Cue Biopharma
75 hedge funds and large institutions have $17.1M invested in Cue Biopharma in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
32% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 22
45% less capital invested
Capital invested by funds: $31M → $17.1M (-$13.9M)
Holders
75
Holding in Top 10
–
Calls
$279K
Puts
$18K
Top Buyers
| 1 | +$279K | |
| 2 | +$274K | |
| 3 | +$191K | |
| 4 |
Millennium Management
New York
|
+$164K |
| 5 |
BL
Bleichroeder LP
New York
|
+$132K |
Top Sellers
| 1 | -$1.84M | |
| 2 | -$723K | |
| 3 | -$518K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$429K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$312K |